BANK VONTOBEL/CALL/ELI LILLY & CO/540/0.1/21.06.24 | Delayed Deutsche Boerse AG 19:02:00 22/05/2024 BST | ||
| 24.19 EUR | -2.85% |
|
| Current month | +5.17% | ||
| 1 month | +26.72% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 22/05/24 | 24.19 | -2.85% |
| 21/05/24 | 24.9 | +9.74% |
| 20/05/24 | 22.69 | +4.66% |
| 17/05/24 | 21.68 | -2.30% |
| 16/05/24 | 22.19 | -1.47% |
Delayed Quote Deutsche Boerse AG
Last update May 22, 2024 at 07:02 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU9H9F |
| ISIN | DE000VU9H9F2 |
| Date issued | 05/07/2023 |
| Strike | 540 $ |
| Maturity | 21/06/2024 (30 Days) |
| Parity | 10 : 1 |
| Emission price | 2.21 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 25.01 € |
|---|---|
| Lowest since issue | 1.44 € |
| Spread | 0.2 € |
| Spread % | 0.80% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
802.9
USD
Average target price
850.4
USD
Spread / Average Target
+5.92%
- Stock Market
- Warrants
- Warrant
